EQ-101

N/A

Report date: 2024/12/31 16:58:00
NMEFirst In Class

Base Information

Drug NameEQ-101
Drug Alias NameBNZ132-1-40BNZ-1BNZ132-1BNZ-01EQ101 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionInterleukin-2 inhibitorsInterleukin-9 inhibitorsInterleukin-15 inhibitors
TargetsInterleukin-2Interleukin-9Interleukin-15
Therapy Area/IndicationsAlopecia AreataAlopeciaLymphoma, T-Cell, Cutaneous +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioniz Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEquillium Aus Pty LtdEquillium IncAlmirall Sa
Inactive CompaniesBioniz Therapeutics Inc
Active IndicationsAlopecia AreataAlopecia
Inactive IndicationsLymphoma, T-Cell, CutaneousLeukemia, Large Granular Lymphocytic

Other Information

ATC CodeN/A
Related LinksN/A